Incident Number: LAB-2025-012
Date of Incident: December 19, 2025
Product Name: Azithromycin (Finished Product)
Batch Number: 33334562222
Test: Related Substances (RS) by HPLC
Analyst Name: Anil Patel (ID: 5122)

I. Incident Description

During the HPLC analysis of Azithromycin Finished Product (Batch No: 33334562222), an Out-of-Trend (OOT) result was observed. The Standard Area was found to be 51,220, which is significantly higher than the theoretical value of 10,035. Because the system suitability criteria were not satisfied, the analytical sequence was aborted and an internal investigation was initiated.

II. Root Cause Analysis (RCA)

A comprehensive review of the analytical process was performed, and the following findings were documented:

  • Preparation Review: The volumetric measurements performed during standard preparation were audited.

  • Dilution Error: It was determined that the final dilution of the working standard was not executed.

  • Calculation Verification: The concentrated stock solution was found to have been injected instead of the final diluted preparation.

  • Conclusion: The root cause was identified as a non-compliance with the dilution steps specified in the Standard Test Procedure (STP).

III. Corrective and Preventive Actions (CAPA)

Corrective Actions:

  • The initial analytical data set was formally invalidated.

  • A fresh standard preparation was performed under the direct supervision of the Laboratory Supervisor.

  • The analysis was re-conducted, and a compliant standard area of 10,038 was obtained.

  • The batch was released only after the re-analysis results were verified and found to be within specifications.

Preventive Actions:

  • Training: Technical retraining on multi-stage dilution protocols was assigned to the analyst.

  • Documentation Update: The analytical worksheets were updated to require a “Dual-Sign-Off” for critical standard dilutions.

  • Instrument Control: A tighter “Area Check” limit has been programmed into the HPLC software to automatically flag deviations exceeding $20\%$ of the historical average.


IV. Final Conclusion

It was concluded that the high area response was caused by a human error during the dilution stage. No impact on the batch quality was identified, as the error was detected prior to sample quantification.

Analytical Method Validation

Analytical method validation ICH Q2(R1) pharmaceutical || HPLC || GC || RS by HPLC || Assay – part-2 (youtube.com)

Question and answer for HPLC

Mobile Application

Paid app
Free app
maheshbhuva

Share
Published by
maheshbhuva

Recent Posts

Just finished a fun session of HPLC calibration!  Time to unwind and rambler a bit about my day.

Play remember all HPLC calibration link given below freeHeadline: Stop Memorizing HPLC SOPs. Start Mastering…

17 hours ago

Dissolution investigation

In pharmaceutical quality control, when a product fails the S1 stage of dissolution (like the…

4 days ago

FDA Propose Rule That Would Help Hold Foreign Tobacco Manufacturers Accountable, Protect Public Health

product dimensions. For e-cigarettes, manufacturers would also need to provide specifications such as e-liquid volume,…

7 days ago

RCA (ROOT CAUSE ANALYSIS) IN PHARMACEUTICAL INDUSTRIES

RCA (ROOT CAUSE ANALYSIS) IN PHARMACEUTICAL INDUSTRIES AS PER REGULATORY REQUIREMENTS 1. PROBLEM IDENTIFICATION What…

3 weeks ago

summary of global nitrosamine regulations FDA, EMA, ANVISA, SWISSMEDC, HEALTHCANDA.

* Nitrosamines are trace chemical impurities. * They are classified as probable human carcinogens. *…

3 weeks ago

Understanding Analytical Method Validation: Interference and Specificity

Specificity This concept is essential in scientific analysis. When you create a method to measure…

4 weeks ago